Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The expanded TCF4 CTG18.1 CUG-repeat RNA is a pathogenic transcript resulting from a trinucleotide repeat expansion within the TCF4 gene, specifically at the intronic CTG18.1 locus (Wieben et al., 2012, PLoS ONE). This expansion, typically exceeding 40-50 repeats, is the most significant genetic risk factor for Fuchs' endothelial corneal dystrophy (FECD), a leading cause of corneal transplant surgery (Vithana et al., 2013, JAMA Ophthalmology). The resulting CUG-repeat RNA molecules accumulate in the nuclei of corneal endothelial cells, forming toxic RNA foci that are a hallmark of the disease (Zarouchlioti et al., 2018, American Journal of Human Genetics). These foci sequester essential RNA-binding proteins, most notably Muscleblind-like 1 (MBNL1), leading to widespread alternative splicing defects and subsequent cellular dysfunction (Mootha et al., 2015, Investigative Ophthalmology & Visual Science). Therapeutic interventions currently under investigation aim to target this toxic RNA using antisense oligonucleotides (ASOs) or small molecules to either induce its degradation or block its interaction with sequestered proteins (Hu et al., 2018, Molecular Therapy). Successfully reducing the burden of these RNA foci is expected to restore normal splicing patterns and preserve the function and density of corneal endothelial cells.
Degradation of toxic expanded RNA via RNase H-mediated cleavage or steric hindrance to prevent the sequestration of RNA-binding proteins like MBNL1.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription factor 4 (TCF4) CTG18.1 expanded CUG-repeat RNA (TCF4 CUG-repeat RNA).